PCAS Biosolution is a joint-venture created in 2006 by PCAS and Protéus with headquarters in Longjumeau, France and operating facilities located in the South of France. PCAS Biosolution aims at providing our customers all the value drivers of integrating biocatalysis into chemical processes.
23, rue Bossuet
Z.I. de la Vigne Aux Loups
Vision & Strategy
PCAS Biosolution integrates chemistry and biotechnology to provide a unique and exclusive offering to the pharmaceutical industry.
The Company combines and integrates multidisciplinary expertise, proprietary technologies and multi-scale production capabilities in both chemistry and biotechnology. We focus on the synthesis of APIs, intermediates and building blocks using chemo-biocatalytic manufacturing routes. Biocatalytic steps provide scalability, versatility and a high chemo-, regio-, stereo- and enantioselectivity.
Benefits include the ability to produce complex intermediates and APIs using scalable routes, reduce manufacturing costs, improve productivity, reduce byproducts and develop competitive green chemistry process.
We are committed to be your quality partner for the development, manufacture and long term supply of your intermediates and APIs using the optimal chemo-biocatalytic routes that meet your specifications of quantity, time, quality and targeted price.
Our mission is to provide significant value to drug developers by designing, developing and implementing new cost-effective and scaleable manufacturing routes to APIs and intermediates which combine both chemistry and biotechnology.
The company aims at creating brand new routes to innovative products or at improving the manufacturing process of currently marketed products. Our focus is on reducing the number of manufacturing steps, decreasing by-products, avoiding hazardous chemicals, using lower cost raw material, enhancing purity and process enantio-selectivity, increasing conversion rate and improving overall yield, energy consumption and performance.
More value also means more Industrial Property: biocatalysts and processes developed are generally proprietary, thus providing opportunities to the drug developers to reinforce and extend the lifetime of their existing intellectual property.
With PCAS Biosolution, your projects will benefit from a unique, comprehensive and integrated chemo-biocatalytic R&D, industrial and regulatory platform.
Source: PCAS Biosolution